General Environmental Science Corp. v. Horsfall

800 F. Supp. 1497, 1992 U.S. Dist. LEXIS 12078, 1992 WL 190797
District Court, N.D. Ohio·Decided May 29, 1992·No. 1:90 CV 1340·Published·Cited by 2 cases

Opinion

ORDER

BATTISTI, District Judge.

This case came before the Court for a hearing on April 21, 1992, on the issue of damages, attorney fees and costs. Based upon the evidence and argument presented at the hearing, together with such evidence already of record in this case, the Court makes the following findings of fact and conclusions of law.

FINDINGS OF FACT

1. General Environmental Science Corporation (“GES”) is a corporation headquartered in Cleveland, Ohio which sells live-liquid micro organism (“LLMO”). The product is sold in the United States and around the world, and is used to treat waste water and aquarium water, among other things. GES also developed and owned a technology known as an on-site activation system. (Transcript of Hearing held April 21, 1992 (“Hearing Trans.”) at 12-13, 75).

2. Beginning in about 1988, GES began selling its LLMO product in Europe through Frank Horsfall (“Horsfall”) and John Strauss (“Strauss”).

3. Between August 1989 and December 1989, Defendants confided in Karl Ehrlich (“Ehrlich”) that they

were entering a contract for distribution with GES that they never intended to honor, and that they planned in the future to break this contract as soon as they could set up their own production facilities and that the would use product variability and potency as a basis for breaking the contract and competing.

(Ehrlich Affidavit at 11 8).

4. In November 1989, Biosys Corporation 1 (“Biosys”), which is owned and controlled by Strauss, Horsfall, and Gustavo Gysler (“Gysler”), signed a contract with GES to be its European distributor of LLMO. (Hearing Trans, at 13-14; Verified Complaint at II14).

5. On or about May 4, 1990, Defendants terminated their relationship with GES, citing product variability and potency (Verified Complaint at ¶ 16). On that same day, Defendants formed a new corporation called Biosphere, S.A.

6. Defendants confirmed the termination of their relationship with GES on May 15, 1990 and began competing with GES.

7. On July 27, 1990, GES filed a complaint against Gysler, Horsfall, Strauss, and Biosys alleging theft of trade secrets, violation of RICO, breach of non-compete *1500 provisions, defamation and various other state tort claims. GES sought actual damages in the amount demonstrated by the evidence, as well as treble damages under RICO and the Ohio Corrupt Activities Act, punitive damages under state law, attorney fees and costs, and injunctive relief. 2

8. On March 10, 1992, 141 FRD 443, the Court entered a default judgment as to liability against Defendants and dismissed the counterclaim of Biosys with prejudice pursuant- to Rule 37(b)(2) of the Federal Rules. The counterclaims of Strauss and Horsfall were dismissed with prejudice on April 7, 1992. As a further sanction, Defendants and their counsel were ordered to pay all of the attorney fees and costs incurred by Plaintiff in this case.

9. On April 21, the Court held a hearing on the issue of damages, attorney fees and costs.

10. GES presented the following evidence: (1) testimony of GES President Barton Gilbert; (2) affidavit of economist John Burke, Ph.D.; (3) exhibits pertaining to GES product ordered by Defendants but never paid for; (4) references to the Gysler’s deposition testimony; (5) affidavit of Barton Gilbert as to attorney fees, costs and other economic damages; (6) affidavits of counsel Jerome F. Weiss, Esq., William T. Davis, Esq., Niki Z. Schwartz, Esq., and Richard L. Stoper, Esq., as to attorney fees and costs; and (7) affidavit of Karl F. Ehrlich.

11. Defendants, represented by counsel, presented no evidence other than references to the transcript of Gysler’s deposition.

12. Stephen Walters, Esq., Thomas C. Buford, Esq., and Jason C. Blackford, Esq. were present for all or part of the hearing and presented no evidence. The law firm of Weston, Hurd, Fallon & Paisley was represented by counsel at the hearing, but presented no evidence.

13. Specifically, GES seeks damages for (1) product ordered and shipped but not paid for; (2) lost profits on European sales of LLMO; and (3) lost revenues resulting from Defendants’ use of GES’s on-site activation system technology.

14. Defendants ordered and received LLMO product from GES totaling $41,-214.50. Defendants never reimbursed GES for these items. (Hearing Trans, at 44; Hearing Exhibit 4).

15. GES has been unable to re-establish its business in Europe as a result of Defendants’ illegal competition, Defendants’ theft of customers with whom they had primary contact as a distributor, and this lawsuit. (Hearing Trans, at 41). GES has been unable to re-establish a distribution network. Id. at 43.

16. GES presented evidence of its historical sales of LLMO in Europe to establish its lost profits. GES sales of LLMO in Europe increased from $17,339 for the year May 15, 1985 through May 15, 1986, to $173,334 for the year May 15, 1989 to May 15, 1990. 3 During this period, GES sales in Europe grew at an annual compounded growth rate of nearly 78 percent. Id. at 23.

17. During the year after Defendants began the unlawful activity alleged in the complaint, GES sales in Europe fell to $44,-635. Sales for the year May 15, 1991 to present fell further to $32,308. Id. at 24.

18. GES presented the affidavit of John F. Burke, Jr. (“Dr. Burke”), Associate Professor of Economics at Cleveland State University. Dr. Burke has an M.A. and Ph.D. in Economies from the University of Notre Dame and has been an associate professor at Cleveland State University since 1970. Dr. Burke has been the recipi *1501 ent of several awards, is a member of several professional organizations, and has authored several articles and papers. Dr. Burke has also presented testimony to several legislative bodies.

19. In preparing his affidavit, Dr. Burke reviewed “industrial data available from Dunn & Bradstreet Credit Services and actual financial statements of [GES] from the fiscal year ending 1987 through the month ending August 31, 1991, including actual sales history in Europe.” (Burke Affidavit at ¶ 3).

20. Based on his review of this data, Dr. Burke projected potential lost sales suffered by GES as a result of the activities alleged in the Verified Complaint and the lost sales already demonstrated by the record of GES sales.

21. In projecting lost sales, Dr. Burke assumed that actual sales would “catch up” to projected sales by 1996. Id. at 119.

22. Dr. Burke projected sales at three different rates: (1) 30 percent which was' the average annual growth rate set forth by GES and Biosys in their 1989 contract in order to permit the parties to renew the contract from year to year; (2) 77.8 percent which was the historical annual growth rate for GES’s sales in Europe; and (3) 50 percent which was a midpoint between the first and second rates. Id.

Free access — add to your briefcase to read the full text and ask questions with AI

General Environmental Science Corp. v. Horsfall, 800 F. Supp. 1497, 1992 U.S. Dist. LEXIS 12078, 1992 WL 190797 (N.D. Ohio 1992).

800 F. Supp. 1497 (General Environmental Science Corp. v. Horsfall) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

General Motors Corp. v. Ignacio Lopez De Arriortua
948 F. Supp. 670 (E.D. Michigan, 1996)
Okocha v. Fehrenbacher
655 N.E.2d 744 (Ohio Court of Appeals, 1995)